- 작성자 : ILIAS Biologics
- 작성일 : 20-09-28 16:12
- 조회 : 440회
28 Sep 2020
ILIAS Biologics Closes $20.6 Million Series B Financing
ILIAS Biologics Inc. has completed a Series B financing round of $20.6 million in South Korea. ILIAS has raised a total of $40.2 million of capital since its foundation in November 2015. This financing will support the continued development of ILIAS’s proprietary EXPLOR® platform technology and the advancement of exosome-based therapeutics pipeline.
The support from our new and existing investors is a reflection of their confidence in the immense potential of ILIAS’s exosome-based platform technology and the expertise of scientists and management teams at ILIAS. ILIAS will continue to work toward fulfilling our mission of transforming scientific imaginations into reality to advance human health.
Please find the link below for more information.